The investigators have recently discovered a genetic variant in an adrenergic receptor that
leads to increased risk for type 2 diabetes. The investigators have also seen that blockers
of that receptor improves impaired insulin secretion in animals. The investigators will now
test the blocker in patients with type 2 diabetes with or without the risk variant in an
effort to make diabetes treatment more individualized.